JOIN OUR TEAM

Tag: MiraLax

Nonprescription Drugs Cost Structures

OTC Industry Looks to High-Growth OTC Switches to Fuel Industry Growth

Over the past few years, Rx-to-OTC switch products have emerged as a major growth driver in the U.S. OTC drug industry. While overall industry growth moderated to just 2.2% in 2008-2009, growth for Rx-to-OTC switches shot up by more than 12%. On the heels of numerous successful switches like Prevacid 24 Hour, Zegerid, Alli, and MiraLax, manufacturers have begun looking ahead at potential switch candidates much earlier in the Rx product life cycle. And with good reason: while the OTC market as a whole is expected to gain with just a CAGR of 2.6% over the next five years, future switches are set to explode by nearly 75%, adding more than $1.5 billion in absolute dollars to the OTC market.

Know More »
Play Video
Play Video